• Improving Patient 
    Outcomes in
    Solid Tumor
    Cancer Treatment

    BIO300
    A New Class of Cancer Drug

  •  

    COVID-19

     

    BIO300
    Preventing long term lung damage caused by inflammation

  • Keeping America Safe

    BIO300
    Protecting Civilians, First Responders and Our Military
    from Nuclear Accidents and Terrorism

Humanetics News

06.21.2022

US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure
Read More

05.18.2022

Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
Read More

04.26.2022

Humanetics Corporation Publishes New Data Comparing BIO 300 with Neulasta
Read More

04.13.2022

Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors
Read More

10.26.2021

Humanetics Corporation Adds Two New Experts to its Board of Directors
Read More

09.22.2021

Humanetics Corporation Completes Phase 1 Trial
Read More

08.24.2021

Humanetics Corporation's BIO 300 Receives Fast Track Designation from FDA
Read More

06.02.2021

Humanetics Corporation Receives Funding from Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer
Read More

01.25.2021

Humanetics Corporation Receives Funding from Department of Defense to Test Drug Against COVID-19
Read More